Peter Grebow

Dr. Grebow has held senior management positions with Cephalon Inc. (now Teva), a biopharmaceutical company, which he joined in January 1991 and served in key positions that included Senior Vice President, Worldwide Business Development; Senior Vice President, Drug Development; Executive Vice President of Technical Operations, and Executive Vice President of Cephalon Ventures until 2011.

Prior to joining Cephalon, he served as the Vice President, Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., from 1986 to 1990. Dr. Grebow has also served as a Member of the Board of Directors of Optimer Pharmaceuticals , Inc. from 2009 until its acquisition by Cubist Pharmaceuticals in 2013 (now Merck), Gen Spera, Inc. from 2012 to 2018, and Complexa, Inc. from 2012 to 2017. He has also served as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. from 2013 to 2017 and is a member of the Investment Advisory Board of the Harrington Discovery Institute since April, 2014. Dr. Grebow currently serves on the Board of MAGiQ Therapeutics, a joint venture between Q Therapeutics and REPROCELL.

Dr. Grebow received his undergraduate degree from Cornell University, a Masters of Science in chemistry from Rutgers University, and a Ph.D. in physical biochemistry from the University of California, Santa Barbara.